Kircik Leon H
J Drugs Dermatol. 2017 Aug 1;16(8):s113-s114.
Increased understanding of psoriasis has led to a shift in treatments from non-specific immunosuppressants to targeted biologics. Studies in psoriasis have demonstrated minimal risk and substantial benefit. As a result, dermatologists and patients are more frequently choosing biologics as first-line treatments for moderate-to-severe disease as our biologics options have recently increased.
.对银屑病认识的加深促使治疗方法从非特异性免疫抑制剂转向靶向生物制剂。银屑病研究表明，其风险极小而益处显著。因此，随着我们生物制剂选择的增加，皮肤科医生和患者越来越频繁地选择生物制剂作为中重度疾病的一线治疗方法。
